Regulatory Catalysts

The regulatory catalyst — the most overlooked

Regulatory catalysts are the most overlooked type of investment event. While product launches and M&A get a lot of attention, regulatory changes often fly under the radar — until they strike. An FDA approval for a drug can create billions in value overnight. A ban on a business model can crush a company. The EU's Digital Markets Act (DMA), which entered into force in March 2024, forces Apple to allow alternative app stores in Europe — Apple services accounting for 5-15% of global revenue can be affected. At the same time, the DMA benefits Swedish companies like Spotify (which can offer direct subscriptions without Apple's 30% 'tax'). These are regulatory catalysts: discrete, time-bound events that fundamentally change a company's regulatory environment. AstraZeneca's Covid vaccine was approved by the EMA in January 2021 — this regulatory approval opened a market of $4-6 billion annually. The company's stock rose 8% in a week. Telia won the 5G spectrum auction in Sweden in November 2021 for 3,2 billion kronor — this regulatory permit enabled Telia's 5G build-out 2022-2025. Boliden got the environmental permit for the Aitik expansion in 2010 — this enabled a production expansion from 36 to 45 million tonnes annually. As an analyst you MUST understand regulatory catalysts — they are often the biggest price drivers for the Swedish stock exchange, especially for pharmaceuticals, telecom, mines, and finance.

📖 DEFINITION

A regulatory catalyst = an upcoming legislative change, approval, or regulation that affects the company positively or negatively. Examples: FDA approval, 5G auction, environmental permit, banking licence, data protection rules.

Positive vs negative catalysts

Regulatory catalysts come in two directions. Positive catalysts: legislative changes or approvals that BENEFIT the company. Examples: FDA approval of a new drug opens a market; the EU's green technology support benefits battery manufacturers; a 5G licence gives telecom companies the right to build a new network; tax relief for R&D increases profitability. Negative catalysts: legislative changes that HARM the company. Examples: ban on fossil fuels (hits oil companies); stricter data protection (hits advertising platforms like Meta); higher bank capital requirements (hits banks); environmental permit withdrawn (closes a mine). Evolution Gaming faced regulatory risk in 2021-2022 when the UKGC (UK Gambling Commission) tightened the rules for live casino — the stock fell 40% over 6 months. SAAB got a negative catalyst in 2019 when Sweden decided not to export weapons to certain countries — the export pipeline shrank by 30%. As an analyst, identify the DIRECTION of a regulatory catalyst: positive (buy) or negative (sell/avoid). This is fundamental — many investors only look at 'approval' and forget that the same approval can be positive for one player and negative for the competitor. AstraZeneca's vaccine approval was positive for AstraZeneca but negative for competitors with older vaccine technology.

💡 INSIGHT

Regulatory catalysts are often zero-sum games: positive for one player, negative for another. The EU's DMA benefits Spotify but harms Apple. FDA approval benefits the patent holder but harms generic manufacturers. Identify who benefits and who is harmed.

Swedish regulatory milestones

⚡ KEY INSIGHTS Regulatory catalysts are the most overlooked type of investment event Positive (approvals, licences) vs negative (bans, tightening) — identify the direction Often a zero-sum game: positive for one player, negative for the competitor Swedish examples: AstraZeneca (EMA), Telia (5G), Boliden (environment), Evolution (UKGC) 2

The approval process — three phases

A drug goes through three clinical phases before approval. Phase I: safety test on 20-100 healthy volunteers. Answers: is the drug safe? Typical duration 1-2 years, cost $10-30M, probability of next phase 60-70%. Phase II: efficacy test on 100-500 patients with the disease. Answers: does the drug work? Duration 2-3 years, cost $30-100M, probability 30-50%. Phase III: large scale test on 1 000-5 000 patients. Answers: is the drug effective and safe at large scale? Duration 2-4 years, cost $100-500M, probability of approval 60-85%. After Phase III the company applies for approval with the FDA (US) or EMA (Europe). The FDA has PDUFA dates — a target date for the decision, usually 6-10 months after the application. The EMA has the corresponding CHMP opinion (Committee for Medicinal Products for Human Use) which comes 6-12 months after the application. Total cycle: from preclinical research to approval takes 10-15 years and costs $1-2 billion per approved drug. Probability from preclinical to approval: ~10%. AstraZeneca's vaccine was an exceptionally fast process — from research start March 2020 to approval December 2020 (9 months), enabled by Operation Warp Speed and existing adenovirus technology from Oxford.

📖 DEFINITION

PDUFA date (Prescription Drug User Fee Act date) = the FDA's official target date for the approval decision. Known 6-12 months in advance. CHMP opinion = the EMA's corresponding statement, coming the month before the final EU decision.

Risk-adjusting the probability of approval

The probability of approval varies dramatically depending on phase and therapy area. Industry standard: Phase I → approved 10-15%; Phase II → approved 30-40%; Phase III → approved 60-85%. But there are large variations between therapy areas. Oncology (cancer): higher approval rate (70% in Phase III) because primary endpoints are clear (overall survival, progression-free survival). Neurology (Alzheimer's, Parkinson's): lower rate (40-50% in Phase III) due to complex endpoints and high placebo response. Cardiology: medium rate (60-70% in Phase III). Infectious diseases: high rate (75-85% in Phase III) due to clear microbiological endpoints. AstraZeneca's vaccine had a typical infectious disease probability of ~80% at Phase III start, which justified the stock's rise March-December 2020. A neurological project with 40% probability at Phase III would have justified a much smaller rise. As an analyst: adjust the probability of approval by therapy area. Always ask: 'Is the primary endpoint clear? Is the historical approval rate for this type of indication high?' Companies with 'strong Phase III data' (statistical significance p<0,001, large effect size, few side effects) have a higher probability (85-95%) than companies with 'marginal data' (p=0,04, small effect size) (50-60%).

✓ TIP

Adjust the probability of approval by therapy area: oncology 70%, infection 80%, cardiology 65%, neurology 45%. Always read the Phase III primary endpoint: p<0,001 = strong data (probability 90%+); p=0,04 = marginal (probability 55-65%).

EMA vs FDA — geographical differences

The FDA (US) and EMA (Europe) have different processes and sometimes different outcomes. FDA: faster process (PDUFA 6-10 months), more transparent (public meetings, published review documents), more inclined to approve 'breakthrough' therapies. EMA: slower (12-18 months), less transparent, stricter requirements on long-term safety. Differences in outcomes: ~80% of drugs approved by the FDA are also approved by the EMA; ~70% of EMA-approved are approved by the FDA. AstraZeneca's vaccine was approved first by the EMA in January 2021, then by the FDA in February 2021 — similar processes but different timelines. Some drugs are approved by the FDA but not the EMA (or vice versa). Example: Provenge (cancer vaccine) approved by the FDA 2010 but declined by the EMA 2013 due to a different assessment of clinical significance. This creates complexity: a company can have FDA approval but not EMA, which limits the market to the US. As an analyst: identify which markets the company is targeting. Companies with 'global filing' (seeking approval in both the US, Europe, and Japan) have greater upside than companies with only 'US filing' or 'EU filing'. Always read the prospectus: 'Biologics License Application (BLA)' for the FDA, 'Marketing Authorisation Application (MAA)' for the EMA. Companies applying to both authorities simultaneously ('rolling submission') have potential for a broader market.

⚡ KEY INSIGHTS Three clinical phases: I (safety, 60-70%), II (efficacy, 30-50%), III (scale efficacy, 60-85%) PDUFA date (FDA) and CHMP opinion (EMA) are known 6-12 months in advance Probability of approval varies by therapy: oncology 70%, neurology 45%, infection 80% FDA (faster, more transparent) vs EMA (slower, stricter) — sometimes different outcomes 3